Standardizing Integration in Psychedelic Therapy Trials

Integration in Psychedelic-Assisted Therapy

Integration is a critical component of psychedelic-assisted therapy (PAT), yet it remains inconsistently defined and reported in clinical research. A recent scoping review published in July 2026 underscores the need for standardized integration practices to improve participant safety and trial efficacy. This review analyzed 44 studies, including 30 clinical trials, and found significant variability in how integration is described and implemented.

Mechanisms and Context of Integration

Integration involves revisiting and incorporating the insights from psychedelic experiences into daily life. The review identified that most studies offered 1-4 integration sessions per psychedelic dose, with sessions typically lasting 1-3 hours. Psilocybin was the most frequently studied psychedelic, with 37 publications addressing its use. However, the reporting on integration content, therapeutic conduct, and facilitator training was minimal, particularly outside psilocybin trials.

Implications for Policy and Research

The lack of standardized integration protocols poses challenges for advancing psychedelic therapy research. The review calls for detailed protocols and consistent reporting of integration practices to facilitate cross-trial comparisons and support progression to phase III trials. Standardized reporting would also enhance participant safety and continuity of care, addressing a critical gap in current research practices.

Risks and Unknowns

The variability in integration practices raises concerns about the safety and efficacy of psychedelic therapies. Without standardized protocols, it is difficult to ensure consistent therapeutic outcomes or compare results across studies. This inconsistency can hinder the development of evidence-based guidelines and delay the broader acceptance of psychedelic therapies in clinical settings.

Future Directions

Moving forward, researchers and clinicians must prioritize the development of standardized integration protocols. This includes specifying session goals, timing, facilitator roles, therapist qualifications, and fidelity monitoring. Such efforts will not only improve the safety and efficacy of psychedelic therapies but also support their integration into mainstream mental health treatment.